Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997761 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
A Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia, sponsored by Brian Jonas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02997761: Recruiting Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia, sponsored by Brian Jonas.
NCT02997761 is a Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Brian Jonas. The registered enrollment target is 20 participants, below the 908-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997761, a Phase 2 study of Philadelphia Chromosome Positive and Adult B Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Brian Jonas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
Primary Outcome
Defined as the number of participants who achieve CR according to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia (ALL), Version 2.2015
Conditions Studied
Interventions
- BIOLOGICAL Blinatumomab
- DRUG Ibrutinib
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
What NCT02997761 shows while recruiting
NCT02997761 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 908-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Philadelphia Chromosome Positive appearing as the primary indexed condition, and to 2 interventions - of which Blinatumomab is the first listed.
NCT02997761 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02997761 about?
NCT02997761 is a clinical study titled "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia". This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibod...
What is the current status of trial NCT02997761?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-06-27. Estimated completion is 2025-09.
What conditions does trial NCT02997761 study?
This clinical trial studies the following conditions: Philadelphia Chromosome Positive, Adult B Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02997761?
The interventions under investigation include: Blinatumomab (BIOLOGICAL), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02997761?
This trial is sponsored by Brian Jonas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997761 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Philadelphia Chromosome Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02997761's enrollment target sits among peer trials
20 11th of 11 higher than 1 of 11 other Philadelphia Chromosome Positive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Philadelphia Chromosome Positive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RECRUITING · Phase 2
-
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI